Xenetic Biosciences, Inc. (NASDAQ: XBIO) has announced the pricing of an underwritten offering of 735,000 shares of common stock at $6.12 per share, expecting to raise approximately $4.5 million in gross proceeds before expenses. All shares are being offered by Xenetic, with Canaccord Genuity LLC serving as the sole bookrunner for the transaction. The company plans to use the net proceeds for working capital and other general corporate purposes.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-25-007528), on October 14, 2025, and is solely responsible for the information contained therein.